Epic Care is pleased to announce the availability of Optune (Formerly NovoTTF-100A System), a ground breaking anti-cancer therapy for the treatment of recurrent glioblastoma (GBM).
Optune is a portable, non-invasive anti-mitotic system approved for use in recurrent GBM patients 22 years of age and older. It is a treatment option for patients with recurrent glioblastoma whose disease has progressed after surgery and radiation options have been exhausted and after receiving initial chemotherapy.
“Our goal at Epic Care is to treat cancer patients with the best therapies available, so we are pleased to add Optune Therapy to our options for those fighting recurrent GBM,” said Dr. Gautam Prasad. “We know how important quality of life is to patients. Optune is a device they can use in their own homes, and it’s also been found in a clinical study to have fewer side effects typically related to treatment with chemotherapy.”
Optune delivers a novel treatment called Tumor Treating Fields (TTFields), which are frequency-tuned electric fields that have been shown in studies to disrupt the growth and spread of cancer cells. TTFields spares healthy, normal non-dividing brain cells by directing treatment directly to dividing cancer cells in tumors.
Optune is designed for continuous use throughout the day by the patient. The device is recommended to be used for at least 18 hours, and can either be plugged into a wall outlet or can run on batteries for portability.
Recurrent glioblastoma is both the most common and also the most aggressive type of malignant brain tumor, affecting approximately 10,000 people in the United States each year.
The US Food and Drug Administration (FDA) approved the Optune System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically – or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgery and radiation options have been exhausted.
If you or someone you know may benefit from this new treatment option for recurrent glioblastoma, please contact our Dublin office for more information (925) 875-1677.
Patients should only use the Optune system under the supervision of a certified physician properly trained in use of the device. More information is available at www.optune.com